News & Blogs

Commitment to Seniors Opposes CMMI’s Final Rule for GLOBE Drug Pricing Model

Washington, D.C. – October 1, 2026 – Commitment to Seniors (C2S), a project of American Commitment, opposes the final rule for the Global Benchmark for Efficient Drug Pricing (GLOBE) model from the Centers for Medicare and Medicaid Innovation (CMMI). This model effectively imposes price controls on the American health care market by tying U.S. drug prices to prices set by foreign governments. Importing foreign price controls risks American jobs, undermines U.S. leadership in pharmaceutical innovation,…

Learn More

Emulating European healthcare won’t win America the biotech race

As Washington debates new ways to make the nation’s healthcare system work better for Americans, policymakers should keep one question in mind: What would happen if the U.S. stopped being the world’s most attractive place to discover and develop new medicines? The answer is not theoretical. Europe already ran that experiment. For decades, the United States has been the global leader in medical innovation. American researchers, universities, investors and life sciences companies have produced treatments…

Learn More

Medicare Advantage plans shift more costs onto seniors in 2027

People who have a Medicare Advantage plan — and wind up needing care and prescriptions next year — are in for a rude awakening. Medicare Advantage insurers are raising out-of-pocket costs for enrollees, drastically cutting money for dental work and other benefits, and eliminating plans that have broad networks of hospitals and doctors, according to federal data released this week and analyzed by STAT and several investment firms. That could result in more shock for…

Learn More

AARP’s $200 billion mirage: How price controls kill tomorrow’s medicine

AARP, the liberal lobbying organization that touts itself as America’s leading senior advocacy group, wants Democrats to greatly expand the Inflation Reduction Act’s drug price controls if they retake Congress and the White House. To spur left-wing lawmakers into action, AARP recently released a report with an eye-popping conclusion: If Democrats change the IRA to add price controls on just 10 popular medicines that are currently exempt, it could save Medicare nearly $200 billion between…

Learn More

MFN Drug Pricing Won’t Help, But Competition Will

Pharmaceuticals cost more in America than in any other developed nation. But copying Europe’s price controls with Most Favored Nation pricing (MFN) will not fix that problem. Washington should instead focus on a reform that is already reducing patients’ prices: direct-to-consumer (DTC) pharmaceutical sales.

Learn More

If Trump wants to lower drug prices, his obvious free-riding targets are outside the US

President Donald Trump just secured nine new pricing agreements with drug manufacturers that could help reduce what Americans pay for many prescription medicines. The deals demonstrate Trump’s commitment to lowering drug prices for patients. The president’s dedication – and his desire to negotiate with companies individually, rather than imposing broad mandates – is commendable. But his efforts would be better directed at the root cause of high drug prices: foreign countries free-riding on American drug…

Learn More

American patients shouldn’t foot the bill for the world’s medicines

Heading into November, voters rank healthcare costs as their single biggest economic worry. For the first time since Kaiser Family Foundation began tracking the question in 2018, a majority now say they’re specifically anxious about affording their prescriptions. And right now, voters trust Democrats more than Republicans to do something about it, by roughly 12 points, and by a similar margin on drug affordability specifically. Republicans can close that gap. We have the ideas that…

Learn More

The Inflation Reduction Act’s broken promise is still costing patients

When President Biden signed the Inflation Reduction Act into law, his administration promised it would make prescription drugs more affordable and accessible for seniors. Yet the results tell a different story. A recent analysis found that nearly one in four initial attempts by patients to fill a prescription for one of the first drugs selected for Medicare’s drug price negotiation program was rejected. Patients relying on immunology and oncology treatments felt this even more intensely,…

Learn More